In addition, we found that besides FVIII concentrates, PCCs were also prescribed to patients with hemophilia A. This could be because inpatients with hemophilia A with inhibitors, the most severe complication of hemophilia [38], have been treated with PCCs as bypassing agents to stop acute bleeding [39]. The gene discussed is F8; the disease is hemophilia.